Research
Hormonal
Statins are safe and beneficial for patients with chronic liver disease (excluding decompensated cirrhosis), improving overall survival and reducing hepatic decompensation risk, contradicting the historical dogma that they are contraindicated.
If you have fatty liver disease and high cholesterol or heart disease risk, take your statin as prescribed. It is safe for your liver (unless you have advanced, decompensated cirrhosis) and helps you live longer.
GoodRefutesHIGH confidence
From a liver perspective, the long-standing dogma that statin therapy is contraindicated in patients with CLD has been proven to be outdated[63].
Why this rating
Supported by multiple studies showing survival benefits and safety, though specific dosing guidelines for post-transplant are less clear.
Source
Individualized treatment options for patients with non-cirrhotic and cirrhotic liver disease
Lukas Hartl et al. · World Journal of Gastroenterology · 2021
DOI 10.3748/wjg.v27.i19.2281
narrative_reviewCited 4×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Bariatric surgery, specifically Roux-en-Y gastric bypass, resolves non-alcoholic steatohepatitis (NASH) in approximately 85% of patients and regresses liver fibrosis, outperforming conservative lifestyle interventions.Good
- Weight loss of 7-10% through lifestyle interventions (diet and exercise) leads to histological improvement in MAFLD, including reduced steatosis, ballooning, and inflammation.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →